Skip to content

Author

Haijun Yu

We have 5 of 33 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Nov 2026

Engineered T cell-agonist chimera for logic-gated STING activation and augmented cancer immunotherapy.

The efficacy of adoptive T cell therapy against solid tumors is markedly hindered by the immunosuppressive microenvironment. Here, we demonstrate that stimulator of interferon genes (STING) activation in tumor-associated macrophages (TAM) enhances the intratumoral infiltration and cytotoxicity of adoptive T cells. We n...

Fang-Min Chen, Meng-Fang Li, Si-Yuan Ren et al. · 0 citations
Review Open access Oct 2026

Targeting senescence-mediated immune resistance for enhanced tumor immunotherapy

Cellular senescence, a stable state of cell cycle arrest triggered by intrinsic and extrinsic stressors, has emerged as a pivotal regulator of tumor immunity and therapeutic resistance. Senescent cells exhibit pronounced temporal heterogeneity in immune modulation. Early-stage senescence enhances antitumor immunity by...

Si-Yu Chen, Jing Su, Ao-Jia Jin et al. · 0 citations
Sep 2026

The Delivery Strategies for PROTAC.

This chapter systematically examines three progressive tiers of PROTAC delivery using stimuli-activatable moieties, and highlights how these strategies achieve spatiotemporally controlled, tumor-selective protein degradation while minimizing off-tumor toxicity.

Yi-Jing Dang, Ze-Li Long, Jing Gao et al. · 0 citations
Review Open access Sep 2026

Molecular design and delivery of extracellular and membrane protein degradation chimeras.

This Review provides a framework for selecting disease-matched degradation routes and advancing meTPDs from platform-specific demonstrations towards predictable therapeutic modalities by integrating molecular design, receptor biology, intracellular trafficking, delivery and pharmacodynamic considerations.

Shu-Tong Lin, Hui-Ling Zhou, Jia-Yan Qiu et al. · 0 citations
Jul 2026

Molecular Engineering of Stimuli-Activatable Protein Degraders for Precise Cancer Therapy.

This Account systematically summarizes recent advances regarding the rational design of stimuli-activatable protein degraders, and strategically outline the "when and how" of integrating these degraders with nanomedicine platforms to tailor precise cancer therapy.

Jing Gao, Yi Lai, Bo Hou et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.